{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:08:50Z","timestamp":1744870130610},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Agents Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Little is known about the outcome for HIV-associated Hodgkin lymphoma (HIV-HL) as this is less common than HIV-negative lymphoma. Therefore, we performed a multi-center study to analyze the clinical characteristics and outcomes of HIV-HL patients in China. Nineteen cases of HIV-HL were diagnosed and treated at three center and including the sixth people\u2019s hospital of Zhengzhou, Peking union medical college hospital, and Chongqing university cancer hospital, between December 2013 and June 2022. Data on the clinical features, laboratory results, response, and prognosis were collected and analyzed. The median age at diagnosis was 43(22\u201374) years. All patients were infected with HIV through sexual transmission, with ten cases transmitted through man having sex with man (MSM) and nine cases transmitted through heterosexual transmission. Seven patients were diagnosed with lymphoma and found to be infected with HIV. Four cases were in stage III, and fifteen cases were in stage IV. After a median follow up of 46.8(4.0-112.9) months, 17 cases were alive after ABVD regimen chemotherapy combined with combination antiretroviral therapy (cART). The 5-year progression-free survival (PFS) and overall survival (OS) rate were 83.9% and 89.5%,respectively. HIV-HL exhibits an invasive process in clinical practice, and cART combined with ABVD regimen chemotherapy can achieve long-term survival for patients.<\/jats:p>","DOI":"10.1186\/s13027-024-00571-w","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T15:02:21Z","timestamp":1713193341000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcome in patients with HIV-associated Hodgkin lymphoma treated with chemotherapy using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the combination antiretroviral therapy (cART) era: results of a multicenter study from China"],"prefix":"10.1186","volume":"19","author":[{"given":"Lirong","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"issue":"12","key":"571_CR1","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.21.01228","volume":"40","author":"N Louarn","year":"2022","unstructured":"Louarn N, Galicier L, Bertinchamp R, et al. First extensive analysis of (18)F-Labeled Fluorodeoxyglucose Positron Emission Tomography-computed tomography in a large cohort of patients with HIV-Associated Hodgkin Lymphoma: Baseline Total metabolic tumor volume affects prognosis. J Clin Oncol. 2022;40(12):1346\u201355.","journal-title":"J Clin Oncol"},{"issue":"3","key":"571_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/jha2.448","volume":"3","author":"CY Wang","year":"2022","unstructured":"Wang CY, Zhou FL, Zhang LQ, et al. Long-term efficacy and safety of programmed death-1 (PD-1) antibody alone in relapsed\/refractory human immunodeficiency virus-associated Hodgkin lymphoma. EJHaem. 2022;3(3):924\u20136.","journal-title":"EJHaem"},{"key":"571_CR3","doi-asserted-by":"publisher","first-page":"e936267","DOI":"10.12659\/AJCR.936267","volume":"23","author":"O Abidoye","year":"2022","unstructured":"Abidoye O, Ogbuagu H, Varghese M. A rare case of good outcome of Hodgkin lymphoma in a patient with HIV on antiretroviral therapy (ART). Am J Case Rep. 2022;23:e936267.","journal-title":"Am J Case Rep"},{"issue":"1","key":"571_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.12691\/ajmcr-9-1-21","volume":"9","author":"G Hevroni","year":"2021","unstructured":"Hevroni G, Mostel Z, Skwiersky S, et al. HIV-associated Hodgkin lymphoma with a granulomatous bone marrow biopsy: a case report. Am J Med Case Rep. 2021;9(1):83\u20137.","journal-title":"Am J Med Case Rep"},{"issue":"27","key":"571_CR5","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"4","key":"571_CR6","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/clinids\/17.4.802","volume":"17","author":"G Kenneth","year":"1993","unstructured":"Kenneth G, John W, Laurence S, et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Clin Infect Dis. 1993;17(4):802\u201310.","journal-title":"Clin Infect Dis"},{"key":"571_CR7","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Ram\u00edrez RU, Shiels MS, Dubrow R et al. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV, 2017,4,e495\u2013504.","DOI":"10.1016\/S2352-3018(17)30125-X"},{"issue":"23","key":"571_CR8","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.1182\/blood-2010-08-301531","volume":"117","author":"J Bohlius","year":"2011","unstructured":"Bohlius J, Schmidlin K, Bou\u00e9 F, et al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood. 2011;117(23):6100\u20138.","journal-title":"Blood"},{"key":"571_CR9","doi-asserted-by":"publisher","first-page":"798008","DOI":"10.3389\/fonc.2021.798008","volume":"11","author":"CY Wang","year":"2022","unstructured":"Wang CY, Liu J, Liu Y. Progress in the treatment of HIV-associated lymphoma when combined with the antiretroviral therapies. Front Oncol. 2022;11:798008.","journal-title":"Front Oncol"},{"key":"571_CR10","doi-asserted-by":"publisher","first-page":"1153790","DOI":"10.3389\/fimmu.2023.1153790","volume":"14","author":"CY Wang","year":"2023","unstructured":"Wang CY, Wu Y, Liu J, et al. Impact of initial chemotherapy cycles and clinical characteristics on outcomes for HIV-associated diffuse large B cell lymphoma patients: the Central and Western China AIDS Lymphoma League 001 study (CALL-001 study). Front Immunol. 2023;14:1153790.","journal-title":"Front Immunol"},{"issue":"1","key":"571_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/jha2.624","volume":"4","author":"CY Wang","year":"2023","unstructured":"Wang CY, Liang SS, Quan X, et al. HIV-associated Burkitt lymphoma in the combination antiretroviral therapy era: real-world outcomes and prognostication. EJHaem. 2023;4(1):100\u20137.","journal-title":"EJHaem"},{"issue":"10","key":"571_CR12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.7326\/L16-0091","volume":"165","author":"N Lohse","year":"2016","unstructured":"Lohse N, Obel N. Update of survival for persons with HIV infection in Denmark. Ann Intern Med. 2016;165(10):749\u201350.","journal-title":"Ann Intern Med"},{"issue":"33","key":"571_CR13","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1200\/JCO.2011.41.4193","volume":"30","author":"S Montoto","year":"2012","unstructured":"Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30(33):4111\u20136.","journal-title":"J Clin Oncol"},{"issue":"19","key":"571_CR14","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1111\/jcmm.17534","volume":"26","author":"CY Wang","year":"2022","unstructured":"Wang CY, Liu J, Lei HK, et al. Clinical characteristics and outcomes of newly diagnosed patients with HIV-associated aggressive B-cell NHL in China. J Cell Mol Med. 2022;26(19):5067\u201377.","journal-title":"J Cell Mol Med"}],"container-title":["Infectious Agents and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-024-00571-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13027-024-00571-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-024-00571-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T15:04:56Z","timestamp":1713193496000},"score":1,"resource":{"primary":{"URL":"https:\/\/infectagentscancer.biomedcentral.com\/articles\/10.1186\/s13027-024-00571-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["571"],"URL":"https:\/\/doi.org\/10.1186\/s13027-024-00571-w","relation":{},"ISSN":["1750-9378"],"issn-type":[{"value":"1750-9378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"assertion":[{"value":"21 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the institutional review board of Each participating center\u2019s institutional. The patient provided his written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}